Quotient Sciences Limited
Nottingham, NG11 6JS, United Kingdom
NCT Number: NCT05335447
This is a study in healthy male volunteers to assess how a new test medicine is taken up and broken down by the body as well as its safety and tolerability.
Looking for future studies?
Notify Me30 year–64 year
Male
Interventional
Phase 1
Nottingham, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
This list only contains the key inclusion criteria.
Exclusion criteria
This list only contains the key exclusion criteria.
On Day 1, participants will receive a single oral dose of GLPG3667
On Day 1, participants will receive a single microtracer microdose of [14C]-GLPG3667 as an intravenous infusion
On Day 1, participants will receive a single oral dose of [14C]-GLPG3667
Time frame: From Day 1 until at least Day 8 in Period 2
Time frame: From Day 1 until at least Day 8 in Period 2
Time frame: From Day 1 until at least Day 8 in Period 2
Time frame: From Day 1 until at least Day 8 in Period 2
Time frame: From Day 1 until Day 4 in Period 1
Time frame: From Day 1 through study completion, an average of 2 months
Lakefront Biotherapeutics NV
Industry
An Open-label Study in Healthy Male Subjects to Investigate the Metabolism and Excretion Pathways of GLPG3667 Following a Single Oral Dose of [14C]-GLPG3667 and to Determine the Absolute Bioavailability Relative to an Intravenous [14C]-GLPG3667 Microtracer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details